Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 April 2025 | Story Reuben Maeko | Photo Supplied
Dr Mutshidzi Mulondo
Dr Mutshidzi Mulondo, UFS academic in the Division of Public Health within the Faculty of Health Sciences at the UFS.

Dr Mutshidzi Mulondo, an academic in the Division of Public Health within the Faculty of Health Sciences at the University of the Free State (UFS), will make history when she becomes the first academic from the institution to be inaugurated into the Global Young Academy (GYA).

Dr Mulondo is one of two South Africans that are part of the 2025 cohort of incoming members who will be inaugurated to the sought-after prestigious Academy in Hyderabad, India. The other South African is Dr Mbuzeleni Hlongwa, a Senior Research Specialist at the Human Sciences Research Council.

The Global Young Academy is a network institution of the United Nations Scientific Advisory Board which allows young scientists from around the world to collaborate on research, set the global agenda, and contribute to global policies. The GYA develops, connects and mobilises young talent from six continents, and empowers young researchers to lead international, interdisciplinary and intergenerational dialogue and contribute to societal challenges. The GYA aims to elevate the voice of young scientists in evidence-informed and inclusive global, regional and national decision making.

The membership is comprised of passionate young scientists, typically who obtained their PhD degrees three to 10 years earlier, are between 30 to 40 years of age, and in the early stages of their independent academic careers. Members are selected for their scientific excellence and commitment to engage with society, and serve five-year terms.

 

Global Young Academy

“I feel honoured to be selected. The selection further cements the ingenuity of young African scientists and our ability to shape the global agenda. It allows us to envision a future together which leans towards empathy, kindness and unity,” said Dr Mulondo.

The Academy hopes to bridge the gap between established and new academics as well the gap between academics from the Global North and Global South. Further positioning academics from the south for interdisciplinary collaboration and publication in high impact journals to address complex and emerging challenges such as public health issues. The Academy selects young academics who display contribution to research, dedication to serving society and the ability to make an impact on the Academy’s community.

 

Aspirations in the academy

The recognition is testament that Africa is still producing globally competitive academics. This achievement is even better as it comes during the G20 presidency when Africa is showing what the developing world can produce. Coincidentally, Dr Mulondo, was one of the invited speakers at the G20 Research & Innovation Working Group, joining other selected young academics.

According to Dr Mulondo, who won the Zenith Global Health Award under the category ‘Mental Health and Well-being’ last year and was first runner-up in the category Emerging Leader at the South African Health Excellence Award. Academics from Africa have a responsibility to contribute to the development of the continent through evidence-based advice and solutions to policymakers. This membership allows young academics to stay in touch with global scientific trends and shifts in order to be better informed about resolving some of humanity’s most pressing crises.

She hopes to continue to advance public health strategies that prioritise mental health and health equity. With geopolitical complexities, climate changes and technological advancements shaping our future, the Academy allows for voices from the Global South to contribute to global policies and influence global policy decisions. “As a mentor and supervisor of master’s and PhD students in Public Health, I hope to contribute to ushering in a new generation of well-rounded public health researchers who are societally engaged.”

Prof Anthea Rhoda, UFS Deputy Vice-Chancellor: Academic, congratulated Dr Mulondo, saying the UFS is extremely proud of her. “Being selected as one of two South African scholars to the Global Young Academy demonstrates her dedication as a public health scholar passionate about making a difference in the health and well-being of society. Well done, on this great achievement.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept